argenx rises on positive Phase III results for efgartigimod

UBS upgraded Argenx (ARGX) to 'Buy' with a $1,400 price target, citing strong Vyvgart franchise prospects and potential $20B peak sales. ARGX shares are up over 50% YTD. UBS also noted the company's expanding pipeline, including empasiprubart, addressing concerns about reliance on Vyvgart.

UBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.

UBS upgraded argenx SE (ARGX) to Buy from Neutral, raising its 12-month price target to $1,400 from $960. The firm projects a $20B peak sales opportunity for the company's flagship product, Vyvgart.

UBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

Argenx (ARGX) reported positive Phase 3 trial results for Vyvgart Hytrulo in treating autoimmune myositis, meeting primary endpoints for IMNM but not DM. The stock surged over 20%. Argenx has multiple late-stage trials and acquisitions in progress, with analysts largely bullish but price targets reflecting modest upside.